Hippo Holdings's 15min chart shows bearish trend with KDJ Death Cross and Marubozu.

According to the 15-minute chart of Hippo Holdings, a technical indicator known as the KDJ Death Cross has been triggered. Additionally, the stock has exhibited a bearish Marubozu pattern, which occurred on October 16th, 2025 at 3:15 PM. This suggests a shift in momentum towards the downside, potentially leading to further decreases in the stock price. Sellers have taken control of the market, and it is likely that the bearish momentum will continue.

Pulmatrix Inc. (PULM), a clinical-stage biopharmaceutical company, recently announced its third quarter 2025 financial results and a divestment plan for migraine and inhalation assets. The company reported zero revenue for Q3 2025, a significant decrease from the $1.6 million reported in Q2 2025. Research and development expenses were reduced to under $0.1 million, down from $2.8 million year-over-year, according to Stocktitan.

As part of its merger strategy with Cullgen, Pulmatrix is planning to divest its inhalation assets, including the proprietary iSPERSE™ technology and three clinical programs. The merger, which was approved by stockholders on June 16, 2025, awaits Nasdaq and China Security Regulatory Commission approval. Post-merger, the combined entity will focus on targeted protein degrader therapies with three Phase 1 clinical programs, Stocktitan reported.

Pulmatrix's cash position of $5.8 million as of June 30, 2025, is expected to fund operations through the merger closing. The company's iSPERSE™ technology portfolio includes 149 granted patents, with 19 U.S. patents expiring between 2024 and 2037, plus approximately 50 pending applications.

The merger with Cullgen is expected to create a Nasdaq-listed company focused on targeted protein degradation technology. The combined entity will have approximately $65 million in cash, providing funding through multiple clinical milestones and runway through 2026. The merger includes three degrader programs approaching or in Phase 1 clinical trials - two for cancer treatment and one for acute and chronic pain.

Pulmatrix's stock price has been volatile, with a significant drop observed in the past quarter. The stock price as of October 15, 2025, is $4.7582, with a market cap of approximately $17.9 million. Technical indicators such as the KDJ Death Cross and the bearish Marubozu pattern suggest a shift in momentum towards the downside, potentially leading to further decreases in the stock price.

Investors should closely monitor Pulmatrix's progress and the regulatory approval process for the merger. The company's financial health and strategic direction will continue to influence its stock price and market position.